KYMR Stock Kymera Therapeutics, Inc.
STRONG BUY US · NasdaqGMInsider buying and pipeline depth support upside if clinical execution stays on track.
Future value: $139.35 (+21.34%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Insider buying after financing and pipeline progress.
- ▾Below 50-day MA (-0.11%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (79.6% of range) — strength
- ▸~21% upside to price target
Is KYMR a buy right now?
Trend: KYMR is trading below the 50-day average (-0.10%), RSI 62 — neutral momentum, with a 3-month return of +8.18%.
Valuation & quality: Kymera Therapeutics, Inc. trades on forward P/E -22.5, price-to-book 6.30; fundamentals show net margin -285.3%, return on equity -24.2%, revenue growth 466.4% year on year.
Analyst consensus: 23 analysts have a mean 12-month price target of $139.35 (+21.3% vs the last close; range $111.00 – $180.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 4) — Insider buying and pipeline depth support upside if clinical execution stays on track.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -8.80% | -2.70% | +0.40% | +40.80% | -9.80% | +14.90% | -5.90% | +2.70% |
Fundamentals
Analyst price target
Technical signals
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Sector: Healthcare · Industry: Biotechnology · United States · 273 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.